{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T18:59:13Z","timestamp":1770663553066,"version":"3.49.0"},"reference-count":33,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T00:00:00Z","timestamp":1205366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Aims\u2003<\/jats:bold> Study aims were threefold: (i) to determine the feasibility, potential efficacy and safety of topiramate as an aid to smoking cessation; (ii) to examine potential predictors of abstinence including gender; and (iii) to explore topiramate's effects on tobacco withdrawal and post\u2010cessation weight gain.<\/jats:p><jats:p><jats:bold>Design\u2003<\/jats:bold> Randomized, double\u2010blind, placebo\u2010controlled, 11\u2010week clinical trial with a 6\u2010week dosage titration period and 5\u2003weeks of maintenance treatment.<\/jats:p><jats:p><jats:bold>Setting\u2003<\/jats:bold> Single\u2010site, out\u2010patient, randomized clinical trial.<\/jats:p><jats:p><jats:bold>Participants\u2003<\/jats:bold> Thirty\u2010eight adult male and 49 female chronic smokers who smoked an average of &gt;\u200310 cigarettes per day and who were motivated to try to quit smoking.<\/jats:p><jats:p><jats:bold>Intervention\u2003<\/jats:bold> Random assignment to receive either topiramate (<jats:italic>n<\/jats:italic>\u2003=\u200343) up to 200\u2003mg daily in divided doses or placebo (<jats:italic>n<\/jats:italic>\u2003=\u200344) orally combined with brief counseling over an 11\u2010week period.<\/jats:p><jats:p><jats:bold>Measurements\u2003<\/jats:bold> Carbon monoxide (CO)\u2010confirmed 4\u2010week prolonged abstinence rate during weeks 8\u201311. Changes in tobacco withdrawal, body weight and safety parameters were also assessed.<\/jats:p><jats:p><jats:bold>Findings\u2003<\/jats:bold> Overall, no significant increase in the prolonged abstinence rate was detected, but logistic regression analysis indicated significant gender\u2010specific differences. Men treated with topiramate were nearly 16 times more likely to quit smoking than women on topiramate [37.5% versus 3.7%; odds ratio (OR)\u2003=\u200315.6; <jats:italic>P<\/jats:italic>\u2003=\u20030.016] and were roughly four times more likely to quit smoking than placebo\u2010treated men (37.5% versus 13.6%; OR\u2003=\u20033.8; <jats:italic>P<\/jats:italic>\u2003=\u20030.098). Topiramate\u2010treated men reported significantly lower tobacco withdrawal scores than both women taking topiramate and men on placebo. On average, male cessators on placebo gained 3.30\u2003kg, whereas topiramate led to a 0.72\u2003kg weight loss (<jats:italic>P\u2003<\/jats:italic>=\u20030.03). Study discontinuation rates due to adverse events (AEs) were significantly higher in the topiramate group (topiramate 23% versus placebo 2%). The most commonly reported AEs in the topiramate arm were paraesthesia, fatigue, difficulty with concentration\/attention and nervousness.<\/jats:p><jats:p><jats:bold>Conclusions\u2003<\/jats:bold> Topiramate produced gender\u2010specific effects on smoking cessation. Male smokers had markedly greater quit rates than female smokers and men were roughly four times more likely to quit smoking when treated with topiramate as compared to placebo. Topiramate was fairly well tolerated, although higher discontinuation rates were seen. Topiramate's triple effects aiding smoking abstinence, attenuating nicotine withdrawal and preventing post\u2010cessation weight gain might make it a promising agent for treating tobacco addiction, at least in men.<\/jats:p>","DOI":"10.1111\/j.1360-0443.2008.02148.x","type":"journal-article","created":{"date-parts":[[2008,3,13]],"date-time":"2008-03-13T12:23:58Z","timestamp":1205411038000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Preliminary evidence for gender\u2010specific effects of topiramate as a potential aid to smoking cessation"],"prefix":"10.1111","volume":"103","author":[{"given":"Robert M.","family":"Anthenelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Paul E.","family":"Keck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,13]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Causes of Death. Epidemiology and Burden of Disease.","author":"World Health Organization.","year":"2003"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.56"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.1.47"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.8.828"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-6-200109180-00011"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1037\/0278-6133.13.4.354"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1998.00002.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.5.605"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900018733"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(03)00039-1"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02171.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00045-4"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02165.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2004.06.014"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-005-0034-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10000"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2006.01518.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1600"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2004.284"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.2.255"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/14622200410001696556"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.72.4.712"},{"key":"e_1_2_7_24_2","first-page":"22","article-title":"The Mini\u2010International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan D. V.","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_25_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association.","year":"1994"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01879.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1986.01800030107013"},{"key":"e_1_2_7_28_2","volume-title":"Clearing the Air: Quit Smoking Today.","author":"US Department of Health and Human Services.","year":"2003"},{"key":"e_1_2_7_29_2","volume-title":"Transcript of the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Drug Abuse Advisory Committee of the Food and Drug Administration.","author":"Food and Drug Administration (FDA).","year":"1995"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1080\/1462220031000070552"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/14622200500358895"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.09.021"},{"key":"e_1_2_7_33_2","first-page":"123","volume-title":"Obesity and Mental Disorders","author":"Heffner J. L.","year":"2005"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13370-3"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1360-0443.2008.02148.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1360-0443.2008.02148.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:04:00Z","timestamp":1698782640000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1360-0443.2008.02148.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,13]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1360-0443.2008.02148.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1360-0443.2008.02148.x","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,13]]},"assertion":[{"value":"2008-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}